{
    "Case ID": "025901",
    "Crime_Name": [
        "Intellectual Property Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement"
    ],
    "Legal_Issue": [
        "Validity and infringement of claim 4 of Canadian Patent No. 1,304,080"
    ],
    "Governing_Law": [
        "'Old' Patent Act"
    ],
    "Procedural_Stage": [
        "Trial"
    ],
    "Evidence_Assessment": [
        "Expert testimonies, analysis of prior art, evaluation of inventive ingenuity"
    ],
    "Decision_Outcome": [
        "Claim 4 is valid and infringed by Novopharm Limited"
    ],
    "Burden_of_Proof": [
        "On the party challenging the patent's validity"
    ],
    "Credibility_Factor": [
        "Expert witness credibility and technical evidence"
    ],
    "Legal_Rule": [
        "A patent is presumed valid unless shown otherwise; requires novelty, utility, and inventive ingenuity"
    ],
    "Standard_of_Review": [
        "Objective assessment of obviousness based on the perspective of a skilled person"
    ],
    "Procedural_Issue": [],
    "Grounds_for_Claim": [
        "Infringement of patent rights related to S(-) Ofloxacin (levofloxacin)"
    ],
    "Outcome_on_Merits": [
        "In favor of Daiichi Pharmaceutical Co. Ltd."
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [],
    "Review_Standard": [],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Prior art, separation techniques for racemic compounds, efforts by Daiichi, lack of anticipation or obviousness"
    ],
    "Legal_Framework": [
        "Canadian patent law"
    ],
    "Applicant_Challenge": [],
    "Court_Result": [
        "Upheld validity of claim 4; found infringement"
    ],
    "Legal_Rule_Source": [
        "Patent Act (pre-1989)"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Challenged validity of the patent, particularly claim 4"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert testimony, scientific data"
    ],
    "Remedy_Requested": [
        "Damages, injunction, interest"
    ],
    "Outcome": [
        "Damages awarded, pre- and post-judgment interest granted, delayed injunction allowing sale of existing stock for 30 days"
    ],
    "Decision_Authority": [
        "Trial Court"
    ],
    "Remedy_Sought": [
        "Monetary compensation and injunctive relief"
    ],
    "Resolution_Mechanism": [
        "Judicial determination"
    ],
    "Legal_Provision": [
        "Patent Act"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Patent holder (Daiichi Pharmaceutical Co. Ltd.)"
    ],
    "Legal_Provision_Cited": [
        "Canadian Patent No. 1,304,080, Claim 4"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Non-infringement and invalidity due to obviousness and lack of novelty"
    ],
    "Applicable_Process": [
        "Civil litigation"
    ],
    "Outcome_of_Review": [],
    "Pending_Relief_or_Application": [
        "Determination of monetary damages deferred"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Obviousness test: whether a person skilled in the art would directly and without difficulty arrive at the invention"
    ]
}